ALK and non-small cell lung carcinoma: Validation in the GSE31852 dataset subsequently confirmed these findings and further highlighted the significant differences in immune cell regulation, including immune cell infiltration, differentiation, and interactions between never-smokers and smokers.<h4>Conclusions</h4>In patients with unresectable stage III <i>ALK</i>-positive NSCLC, CRT improved the disease control.